Drug Profile
Crovalimab - Chugai Pharmaceutical/Roche
Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Roche
- Class Antianaemics; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Paroxysmal nocturnal haemoglobinuria
- Phase III Atypical Haemolytic Uraemic Syndrome
- Phase II Sickle cell anaemia
- Phase I Lupus nephritis
Most Recent Events
- 26 Mar 2024 Registered for Paroxysmal nocturnal haemoglobinuria in Japan (SC)
- 13 Feb 2024 Roche anticipates regulatory approval for crovalimab in Paroxysmal nocturnal haemoglobinuria in the US and European Union (SC) in 2024
- 13 Feb 2024 Roche intends to launch crovalimab for Paroxysmal nocturnal haemoglobinuria in 2024 (SC)